Evidence map›Paper›PMID 38912474›Full record

ReviewHeliyon2024

Pro-inflammatory responses after peptide-based cancer immunotherapy.

Hanie Mahaki, Hassan Ravari, Gholamhossein Kazemzadeh, Elham Lotfian, Rahele Amir Daddost, Amir Avan, Hamed Manoochehri, Mohsen Sheykhhasan, Reihaneh Alsadat Mahmoudian, Hamid Tanzadehpanah

RetractedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

  • Retraction · 2025-07-16Concerns/Issues about Referencing/Attributions · Investigation by Journal/Publisher · Objections by Author(s) · Unreliable Results and/or Conclusions ·
5 · Who and what money

Authors and funding

10 authors.

Hanie MahakiVascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hassan RavariVascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Gholamhossein KazemzadehVascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Elham LotfianVascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Rahele Amir DaddostCommunity Health Nursing in Hospital Imam Reza, Tabriz, Iran.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamed ManoochehriThe Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran.
Mohsen SheykhhasanCellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran.
Reihaneh Alsadat MahmoudianMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamid TanzadehpanahAntimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic vaccinations are designed to prevent cancer by inducing immune responses against tumor antigens. in cancer cells, tumor-associated antigens (TAA) or tumor-specific (mutated) derived peptides are presented within the clefts of main histocompatibility complex (MHC) class I or class II molecules, they either activate cytotoxic T-lymphocytes (CTLs), CD4

Indexed as

CytokineImmunotherapyNeoplasmsPeptideT-lymphocyte cytotoxicVaccine

Identifiers

PMID38912474
PMCPMC11190603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.